Navigation Links
Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
Date:3/4/2013

LA JOLLA, Calif., March 4, 2013Sanford-Burnham Medical Research Institute (Sanford-Burnham) and 60 Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics. 60 Pharmaceuticals, a philanthropic-for-profit company focused on neglected and rare diseases, agreed to provide funding to Sanford-Burnham for the first phase of research to explore inhibitors of furin.

Since viral genomes are too small to encode every protein needed for their survival, they take advantage of proteins in their human hosts. For the dengue virus and numerous other virusessuch as West Nile, Ebola, or yellow feverfurin is a vital host protein. For this reason, these viruses can only attack human cells that produce furin. Scientists at Sanford-Burnham are now trying to find a way to inhibit furin, making it impossible for the dengue virus to exploit and "hijack" a host cell.

"We're working on a new small-molecule furin inhibitor. It's a challenge to design, but could solve the toxicity problem that plagues existing viral inhibitors," explains Alex Strongin, Ph.D., professor in Sanford-Burnham's Infectious and Inflammatory Disease Center.

During the first phase of the research partnership, Drs. Alex Strongin and Maurizio Pellecchia and their laboratories at Sanford-Burnham will identify the most promising lead candidate from multiple small-molecule compounds they have already synthesized and tested in cell-based tests. They will evaluate each compound's absorption and distribution in the body (pharmacokinetics), as well as toxicity and efficacy in animal models. These data will inform potential second-phase research, which will focus on further developing the lead compound for oral application.

"The partnership with Sanford-Burnham exemplifies our commitment to developing treatments for the world's most
'/>"/>

Contact: Deborah Robison
drobison@sanfordburnham.org
407-745-2073
Sanford-Burnham Medical Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Californias stem cell agency boosts heart disease research at Sanford-Burnham
2. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
3. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
6. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
9. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
10. Researchers pursue red flag for schizophrenia relapse
11. University of Arizona Engineering College pursues water technology innovation cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013 Integrated Biometrics patented LES ... custom thin film transistor camera introduces Sherlock, a ... image in the smallest and lightest form factor ... F Mobile ID FAP 45, Certified scanner is ... size and weight when compared to optical scanners. ...
(Date:5/16/2013)... 23 million years old give unprecedented insight into ... of the most species-rich groups among the modern ... Bettina Reichenbacher from the Division of Paleontology and ... Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany ... which they assign to the group of bony ...
(Date:5/16/2013)... (GWA), where the entirety of an individual,s DNA is ... which can cause health problems is a massively useful ... pose major ethical problems if used incorrectly, say new ... published on line today (16 May 2013) in the ... based on whole genome and on exome* sequencing and ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... awarded today at the IOF WCO-ECCEO10 Congress in Florence ... award honours an individual researcher who has significantly advanced ... work. It underlines an important aspect of IOF,s mission ... to promote medical innovation, scientific excellence and improved care. ...
... director of the Walter and Eliza Hall Institute from ... in the institute,s Molecular Genetics of Cancer division. ... Professor Doug Hilton, said he was delighted Professor Cory ... institute are immensely proud of this latest of Suzanne,s ...
... -- (May 6, 2010) -- With thousands of scientists across ... to fight disease, there,s a growing emphasis on finding the ... research from Rice University and the University of Cambridge suggests ... role in hematopoietic stem cells (HSCs), the self-renewing cells the ...
Cached Biology News:Suzanne Cory becomes first-elected woman president of AAS 2Stem cells: In search of a master controller 2
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 IAC Industries wants ... a start up laboratory needing to set up and furnish ... to a larger facility within a year’s time. How does ... that the laboratory is temporary? What is efficient and cost-effective? ... modular workstations from IAC Industries. The planners at DisperSol determined ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... of a series of new, proprietary Quill(TM) SRS ... invasive, gynecology procedures, including hysterectomies and myomectomies. In ... the United States of which approximately 130,000 were ...
... , , SAN DIEGO, Aug. ... scheduled to present at the Canaccord Adams 29th Annual Global Growth ... 2:00 p.m. Eastern Time. , , (Logo: ... these presentations will be accessible on the Company,s website at ...
... N.J., Aug. 4 DOR BioPharma, Inc., (OTC Bulletin ... company, announced today that the Office of Orphan Products ... (FDA) has granted Orphan Drug Designation to Oral BDP ... symptoms associated with chronic Graft-versus-Host disease (cGVHD) in patients ...
Cached Biology Technology:Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 2Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 4Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 5Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 6Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 3DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 4DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 5DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 6
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Blimp-1 (H-150)...
SCP-1 (P-17)...
Biology Products: